|
Localized stages (I–II) |
Advanced stages (III–IV) |
P |
| Mean age (years old) |
64 |
|
| Men (%) |
73.4% |
|
| Smoking habit |
46% former smoker; 39.6% current smoker; 13.1% never smoker |
|
| Histology |
63.8% Adenocarcinoma; 27.7% Squamous; 3.1% Neuroendocrinecarcinoma |
|
| PS 0–1 |
85% |
|
| Stage at diagnosis (%) |
– |
III 28.4% (IIIA 15.8%; IIIB 11.6%; IIIC 1%) |
|
| IV 52.2% |
| Absence of comorbidities (cardiovascular risk factors, stroke, COPD, vasculophaty) |
36.6% |
63.4% |
<0,001 |
| Symptoms (cough, chest pain, dyspnea, hemoptysis, weight loss) |
Infrequent |
Most frequent |
<0,001 |
| Previous exposure, % |
|
|
|
| Arsenic |
65.1 |
87.5 |
0.020 |
| Acrylonitrile |
65.1 |
75 |
0.020 |
| Asbestos |
47.5 |
34.9 |
0.020 |
| Paint |
38.1 |
34.9 |
0.020 |
| Diesel engine fumes |
38.2 |
34.9 |
0.020 |
| History of other tumor(s), % |
47.6 |
34.9 |
0.001 |
| Smoking habit |
|
|
|
| Active smoking habit |
Least frequent |
Most frequent |
0.001 |
| Passive smoking habit |
Least frequent |
Most frequent |
0.003 |
| Mutations |
– |
ALK 30.7% (2012) vs. 64.8% (2018) ROS1 6.7% (2012) vs. 20.7% (2018) EGFR 84.8% (2012) vs. 92.1% (2018) |
0.001 |
